NZ593837A - Recombinantly modified plasmin - Google Patents

Recombinantly modified plasmin

Info

Publication number
NZ593837A
NZ593837A NZ593837A NZ59383708A NZ593837A NZ 593837 A NZ593837 A NZ 593837A NZ 593837 A NZ593837 A NZ 593837A NZ 59383708 A NZ59383708 A NZ 59383708A NZ 593837 A NZ593837 A NZ 593837A
Authority
NZ
New Zealand
Prior art keywords
domain
amino acid
polypeptide
terminal
kringle domain
Prior art date
Application number
NZ593837A
Other languages
English (en)
Inventor
Valery Novokhatny
Original Assignee
Grifols Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Therapeutics Inc filed Critical Grifols Therapeutics Inc
Publication of NZ593837A publication Critical patent/NZ593837A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ593837A 2007-11-29 2008-11-25 Recombinantly modified plasmin NZ593837A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99114807P 2007-11-29 2007-11-29
PCT/US2008/084645 WO2009073471A1 (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Publications (1)

Publication Number Publication Date
NZ593837A true NZ593837A (en) 2013-01-25

Family

ID=40379999

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ593837A NZ593837A (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin
NZ585715A NZ585715A (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ585715A NZ585715A (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Country Status (17)

Country Link
US (3) US8101394B2 (https=)
EP (1) EP2220221B1 (https=)
JP (1) JP5539896B2 (https=)
KR (1) KR101529743B1 (https=)
CN (1) CN101918548B (https=)
AU (1) AU2008331545B2 (https=)
BR (1) BRPI0819780B1 (https=)
CA (1) CA2707266C (https=)
ES (1) ES2534040T3 (https=)
HU (1) HUE024916T2 (https=)
IL (1) IL205936A (https=)
MX (1) MX2010005947A (https=)
NZ (2) NZ593837A (https=)
PL (1) PL2220221T3 (https=)
PT (1) PT2220221E (https=)
WO (1) WO2009073471A1 (https=)
ZA (1) ZA201003730B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102660564B (zh) 2004-04-22 2013-05-08 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
PL2220221T3 (pl) 2007-11-29 2015-07-31 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
MX2010013282A (es) 2008-06-04 2010-12-21 Talecris Biotherapeutics Inc Composicion, metodo y kit para la preparacion de plasmina.
HUE025670T2 (en) * 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
JP6085568B2 (ja) 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
SG11201506886TA (en) 2013-03-14 2015-09-29 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
DE102014112212A1 (de) * 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
FR3035120B1 (fr) * 2015-04-15 2020-02-07 Arcadophta Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition
WO2017101870A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
TWI725092B (zh) 2015-12-18 2021-04-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
TWI624268B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CN108210897A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肺纤维化的药物及其用途
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
JP7175270B2 (ja) * 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
WO2018107688A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
US11154595B2 (en) 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
US11140020B1 (en) 2018-03-01 2021-10-05 Amazon Technologies, Inc. Availability-enhancing gateways for network traffic in virtualized computing environments
WO2020152713A1 (en) * 2019-01-25 2020-07-30 Council Of Scientific & Industrial Research Fibrinolytic composition and method of its preparation
CN115697385A (zh) * 2020-05-11 2023-02-03 泰伦基国际有限公司 一种治疗脊髓性肌萎缩症的方法和药物
CN118308334B (zh) * 2024-06-06 2024-10-08 深圳市卫光生物制品股份有限公司 一种重组人纤溶酶原及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
DE69739304D1 (de) 1996-01-23 2009-04-23 Operon Biotechnologies Inc Verfahren und Zusammensetzungen zur Bestimmung von Sequenzen von Nukleinsäure-Molekülen
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
JP2001511362A (ja) 1997-07-22 2001-08-14 ラピジーン，インコーポレイテッド Ｍｓにより配列決定データを相関させるコンピュータ方法およびシステム
AU751283B2 (en) 1998-07-14 2002-08-08 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin
ATE349226T1 (de) 1998-09-29 2007-01-15 Leuven Res & Dev Vzw Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
AU2001275091A1 (en) 2000-06-02 2001-12-17 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
JP4047170B2 (ja) 2000-12-21 2008-02-13 トロム−イクス・ナムローゼ・フエンノートシャップ 酵母発現ベクターおよび酵母細胞における発現による組換えタンパク質の製造方法
WO2003054232A2 (en) 2001-12-13 2003-07-03 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
DE10390418D2 (de) 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN102660564B (zh) * 2004-04-22 2013-05-08 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
PL2220221T3 (pl) 2007-11-29 2015-07-31 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina

Also Published As

Publication number Publication date
KR20100102135A (ko) 2010-09-20
HK1146089A1 (en) 2011-05-13
IL205936A0 (en) 2010-11-30
US8512980B2 (en) 2013-08-20
BRPI0819780B1 (pt) 2023-01-24
ES2534040T3 (es) 2015-04-16
MX2010005947A (es) 2010-09-10
CN101918548A (zh) 2010-12-15
NZ585715A (en) 2011-11-25
IL205936A (en) 2015-04-30
CN101918548B (zh) 2013-10-16
EP2220221A1 (en) 2010-08-25
US20120276611A1 (en) 2012-11-01
CA2707266C (en) 2013-12-31
US8182808B2 (en) 2012-05-22
BRPI0819780A2 (pt) 2015-08-11
JP2011505140A (ja) 2011-02-24
EP2220221B1 (en) 2014-12-31
AU2008331545B2 (en) 2014-01-16
HUE024916T2 (en) 2016-02-29
WO2009073471A1 (en) 2009-06-11
AU2008331545A1 (en) 2009-06-11
KR101529743B1 (ko) 2015-06-17
US8101394B2 (en) 2012-01-24
US20120093799A1 (en) 2012-04-19
CA2707266A1 (en) 2009-06-11
US20110003332A1 (en) 2011-01-06
PT2220221E (pt) 2015-04-16
ZA201003730B (en) 2012-11-28
JP5539896B2 (ja) 2014-07-02
PL2220221T3 (pl) 2015-07-31

Similar Documents

Publication Publication Date Title
NZ593837A (en) Recombinantly modified plasmin
MA28590B1 (fr) Plasmine a modification par recombinaison
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
NZ601094A (en) Modified cry1ca insecticidal cry proteins
ATE400647T1 (de) C-terminale modifikation von polypeptiden
EP4582442A3 (en) Tnfr2 agonists with improved stability
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
Lesner et al. Sunflower trypsin inhibitor 1 as a molecular scaffold for drug discovery
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
MX2012008148A (es) Conjugados de igf-i poli(etilenglicol).
GB0608368D0 (en) Process for making Oligopeptides
TW200604207A (en) A superantigen fusion protein and the use thereof
BRPI0508916A (pt) polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os
ATE466876T1 (de) Immunogene konstrukte
DE602004004796D1 (de) Expressionsvektoren, transformierte wirtszellen und fermentationsverfahren zur herstellung rekombinanter polypeptide
MX2025005121A (es) Inhibidores de ccr2 y metodos de uso
RU2009143097A (ru) Новые рекомбинантные полипептиды со свойствами плазминогена человека
TORFF et al. Low molecular weight protease
RU2019130404A (ru) Новый рекомбинантный аналог гормона роста пролонгированного действия
KR20150123455A (ko) 효모를 이용한 티모신 베타4의 생산방법

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 NOV 2015 BY DAVIES COLLISON CAVE

Effective date: 20130506

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2016 BY AJ PARK

Effective date: 20151021

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2017 BY AJ PARK

Effective date: 20161006

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2018 BY AJ PARK

Effective date: 20170914

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2019 BY AJ PARK

Effective date: 20180827

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2020 BY AJ PARK

Effective date: 20190828

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2021 BY AJ PARK

Effective date: 20201120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2022 BY AJ PARK

Effective date: 20211012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2023 BY AJ PARK

Effective date: 20221019

LAPS Patent lapsed